Posted by Michael Wonder on 19 Aug 2021
BeiGene announces acceptance by Swissmedic of marketing authorisation application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
18 August 2021 - BeiGene announced that Swissmedic has accepted the marketing authorisation application for Brukinsa, a treatment option for adult patients with Waldenström’s macroglobulinaemia.
Swissmedic has started the formal review of the marketing authorisation application. Brukinsa has already been granted orphan drug status by Swissmedic.
